NYSE:JNJPharmaceuticals
ICOTYDE Psoriasis Data And JNJ-4804 Funding Could Be A Game Changer For Johnson & Johnson (JNJ)
In late March 2026, Johnson & Johnson reported 52-week Phase 3 data showing its oral peptide ICOTYDE maintained high complete skin clearance rates and a consistent safety profile in adults and adolescents with moderate-to-severe plaque psoriasis, while Royalty Pharma announced a US$500 million R&D co-funding agreement to advance JNJ-4804 for autoimmune diseases.
These developments highlight Johnson & Johnson’s push to build a differentiated immunology portfolio, pairing late-stage oral...